Our latest
News
Mauna Kea Technologies Announces Another Milestone Year at Digestive Disease Week® 2025 with 8 Presentations Demonstrating the Clinical Value of Cellvizio® in Key Indications
Mauna Kea Technologies Reports Full Year 2024 Results and Provides a Business Update
Mauna Kea Technologies announces entrance into exclusive negotiations for a licensing agreement for Cellvizio® in an important therapeutic area with a major industry player
Mauna Kea Technologies announces the opening of a safeguard proceeding to restructure its financial liabilities
Cellvizio® Now Recommended in New European Society of Gastrointestinal Endoscopy Technical Guideline for Pancreatic Cyst Diagnosis
Mauna Kea Technologies Announces Promising Results in New Application Combining Robotics and Cellvizio® for Precision Surgery in Head and Neck Cancers
Mauna Kea Technologies Secures Additional U.S. Artificial Intelligence Patent to Strengthen Endomicroscopy IP Complex
Mauna Kea Technologies Reports Full Year 2024 Sales and Provides Strategic Update
Mauna Kea Technologies Announces its 2025 Financial Calendar
Raising Pancreatic Cancer Awareness Through Patient Voices
Mauna Kea Technologies Celebrates Over 700 Procedures Performed in 18 Months at IECED-OMNI Hospital in Ecuador